ArticleArthritis research & therapy2026
Diagnostic utility of salivary gland ultrasonography in suspected primary Sjögren's disease: a comparison of OMERACT-based ordinal and summative scoring.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSalivary gland ultrasonography (SGUS) is a promising, non-invasive tool in the diagnostic workup of suspected primary Sjögren’s disease (SjD). This study aimed to compare the diagnostic accuracy of two SGUS scoring methods - an ordinal score (0–6) and a sum score (0–12) - derived from the OMERACT 0–3 grading system, using labial salivary gland biopsy as the reference standard.
methodsSixty consecutive patients with suspected primary SjD underwent SGUS of the four major salivary glands. Each gland was graded using the OMERACT 0–3 system. Two composite scores per patient were calculated: (1) ordinal score (maximum 6), considering the two most affected glands and (2) sum score (maximum 12), obtained by adding the scores of all four glands. Diagnostic accuracy was assessed using ROC curve analysis, with histopathology as reference.
resultsLabial biopsy was positive in 23 patients (38.3%). The ordinal score yielded an AUC of 0.687 (95% CI: 0.546–0.828), with 91.9% specificity (95% CI: 83.1–100%) at a threshold ≥ 4. The sum score showed an AUC of 0.683 (95% CI: 0.543–0.824), with 89.2% specificity (95% CI: 79.2–99.2%) at ≥ 5. SGUS scores ≥ 2 (ordinal) and ≥ 3 (sum) were significantly associated with anti-Ro52 antibody positivity (p = 0.017 and p = 0.007, respectively). At these high-specificity thresholds, labial biopsy could have potentially been deferred in 16.6% (ordinal ≥ 4) and 21.7% (sum score ≥ 5) of biopsy-positive cases, respectively.
conclusionsAlthough overall diagnostic performance was modest, SGUS scoring based on OMERACT definitions demonstrated high specificity at selected thresholds. These findings support its potential role as a biopsy-sparing tool in selected patients with high pre-test probability and compatible serological profiles. Prospective studies are needed to validate these results and optimize threshold selection.
trial registrationnot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.